Media Articles Related to Fareston (Toremifene)
Exemestane Well-Tolerated for Breast Cancer Prevention
Source: Medscape Medical News Headlines [2014.04.18]
When given to prevent breast cancer in postmenopausal women, the aromatase inhibitor exemestane has little effect on quality of life, according to follow-up results of the MAP.3 trial.
Reuters Health Information
First genetic link discovered to difficult-to-diagnose breast cancer sub-type
Source: Breast Cancer News From Medical News Today [2014.04.17]
Scientists have identified the first genetic variant specifically associated with the risk of a difficult-to-diagnose cancer sub-type accounting for around 10-15 per cent of all breast cancer cases.
New blood test 'accurately predicts breast cancer recurrence'
Source: Blood / Hematology News From Medical News Today [2014.04.15]
Researchers have developed a blood test that they say predicts breast cancer recurrence with up to 95% accuracy and effectively monitors patients' response to chemotherapy.
ZMYND11 'reads' methylated variant to thwart cancer; tied to breast cancer patient survival
Source: Breast Cancer News From Medical News Today [2014.04.15]
A tumor-suppressing protein acts as a dimmer switch to dial down gene expression.
Lung Cancer: A Dose-Dependent Risk After Breast Cancer RT
Source: Medscape Hematology-Oncology Headlines [2014.04.14]
The risk of developing a primary lung cancer after radiotherapy for breast cancer increases in a dose-response manner, with these odds jumping 17-fold in smokers.
Medscape Medical News
Published Studies Related to Fareston (Toremifene)
Toremifene decreases vertebral fractures in men younger than 80 years receiving
androgen deprivation therapy for prostate cancer. 
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer would result in equivalent survival with an improved side effect profile, therefore, providing superior therapeutic efficacy... CONCLUSIONS: Women treated with adjuvant hormonal therapy enjoyed excellent DFS and OS. No significant differences were found between treatment with either tamoxifen or toremifene. Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate. (c) 2010 American Cancer Society.
Cardiovascular safety of degarelix: results from a 12-month, comparative,
randomized, open label, parallel group phase III trial in patients with prostate
gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar
Clinical Trials Related to Fareston (Toremifene)
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
and will continue to compare combined hormonal therapy using the experimental aromatase
inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the
treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via
the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene
(FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying
the growth of breast cancer, and whether the side effects of the combined hormonal therapy
are different from the side effects of letrozole.
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI
findings of the breast in women suffering from premenstrual mastalgia.
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in
reducing the risk of bone fractures in men with prostate cancer who are on Androgen
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]
Reports of Suspected Fareston (Toremifene) Side Effects
Hepatic Function Abnormal (4),
White Blood Cell Count Decreased (4),
Interstitial Lung Disease (3),
Hepatitis Acute (2),
Condition Aggravated (2),
Respiratory Failure (2),
Neoplasm Progression (1),
Osteomyelitis (1), more >>